ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Onconetix, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.43−0.05 (-10.13%)
Close on Oct 19, 2026
- Market cap
- $965.06K
- P/E (TTM)
- –
- Dividend yield
- –
Onconetix, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Development Services [Member] | – | – | – | $544.02K | $948.25K | $1.65M | $2.28M | – | – |
| Product Sales [Member] | – | – | $225.84K | $383.58K | $378.77K | – | $249.03K | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | $38.02K | $33.51K | $18.78K | $28.04K | $22.45K | – | $23.84K | 5.9% | +69.4% |
| Switzerland | – | – | $796.59K | $1.20M | $1.31M | $1.91M | $2.44M | – | – |
| European Union [Member] | – | – | $796.59K | $1.20M | $1.31M | $1.91M | $2.44M | – | – |
| Non-European Union (UK) [Member] | – | – | $18.78K | $28.04K | $23.23K | – | $23.84K | – | – |
From the segment and revenue-disaggregation notes of Onconetix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.